The NIH awarded UTHealth Houston researchers a five-year $4 million grant to study why weight returns after discontinuation of GLP-1 receptor agonists. The project is led by Absalon J. Pineda and aims to dissect the mechanisms behind regain that have become a major clinical concern for obesity medicine. The funding reinforces regulatory and payer focus on longer-term treatment strategies, including whether outcomes can be maintained with dosing schedules, adjunct therapies, or behavioral/physiologic interventions after stopping medication.